YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC 50 s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.

YNT-185 (20-40 mg/kg; i.p.) increases wakefulness in mice[2]. YNT-185 (300 nmol; i.c.v.) significantly increases wake time for 3 hours in a dose-dependent manner, accompanied by a decrease in NREM sleep time, in wild-type mice but not in OXRDKO mice[2]. Animal Model: Male wild-type C57BL/6J mice[2]Dosage: 20, 40 mg/kg Administration: I.p. Result: Wake time was also significantly increased.

1804978-81-1

C33H37N5O5S

615.75

YNT-185

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years